Q1 2025 Avantor Inc Earnings Call
www.microsoft.com.ca Microsoft Mechanics www.microsoft.com.ca
Emily: Good morning, my name is Emily and I will be your conference operator today. At this time I would like to welcome everyone to Avantor's first quarter, 2025, earnings results conference call. After the presentation you will have the opportunity to ask any questions, which you can do so at any time by pressing start, followed by the number one on your telephone keypad.
Speaker Change: I will now turn the call over to Alison Hosek, Senior Vice President of Global Communications. Ms. Hosek, you may begin the conference.
Alison Hosack: Good morning and thank you for joining us. Our speakers today are Michael Stubblefield, President and Chief Executive Officer, and Brent Jones, Executive Vice President and Chief Financial Officer. Good morning and thank you for joining us.
Speaker Change: The press release and a presentation accompanying this call are available on our Investor Relations website at ir.avontorciances.com
Alison Hosack: A replay of this webcast will also be made available on our website after the call. Following our prepared remarks, we will open the line for questions.
Alison Hosack: During this call, we will be making forward-looking statements within the meaning of the U.S. federal securities laws, including statements regarding events or developments that we believe or anticipate may occur in the future.
Alison Hosack: These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings. Actual results might differ materially from any forward-looking statements that we make today.
Alison Hosack: These forward-looking statements speak only as of the date that they are made. We do not assume any obligation to update these forward-looking statements as a result of new information, future events or other developments.
Alison Hosack: This call will include a discussion of non-GAAP measures . A reconciliation of these non-GAAP measures can be found in the press release and in the supplemental disclosure package on our investor relations one site. With that, I will now turn the call over to Michael. Thank you, Paul.
Michael Stubblefield: Thank you, Allie. Good morning, everyone. I appreciate you joining us today. Before we get into our first quarter results, I want to address the CEO transition announcement we made this morning.
Michael Stubblefield: After careful consideration, our Board of Directors and I agreed that now is the right time to initiate a transition in Avantor's leadership.
Michael Stubblefield: The board has initiated a search process to identify the company's next CEO , and will look for someone who has a strong track record of delivering growth and value creation. A plan to step down once a successor is in place and in committed to a smooth transition. [inaudible]
Michael Stubblefield: In the meantime, as I will discuss in detail shortly, our entire leadership team is focused on taking steps to accelerate growth and strengthen the business.
With that, let's turn to slide three.
Michael Stubblefield: I want to acknowledge that we are not satisfied with our first quarter performance. Thank you very much.
Michael Stubblefield: While we delivered earnings and margin in line with our plan, revenue in both segments fell short of our expectations.
Michael Stubblefield: We entered 2025 with a clear focus on innovation-driven growth, margin expansion, and de-leveraging. However, sentiment in some of our end-markets, particularly education and government, turned cautionary as customers reacted to policy changes announced by the new administration.
Michael Stubblefield: Also, funding fell approximately 40% in the quarter for bench stage biotech companies, leading to additional demand weakness for this important customer segment in our biopharma end market. Thank you very much.
Michael Stubblefield: We expect this market backdrop to continue, pressuring demand for the foreseeable future, which is reflected in reset guidance.
Michael Stubblefield: While we cannot change the market environment, we intend to take every action within our control to enhance growth in both lab solutions and bioscience production, while continuing to expand margins and reduce leverage.
Michael Stubblefield: Specifically to our lab business, we are making immediate and significant changes to drive growth.
Michael Stubblefield: We're excited to have Cory Walker, President of Lab Solutions, fully onboarded. Given his prior experience with our business, he has ramped quickly and is conducting a deep dive into the business, evaluating every aspect of our strategy and execution. Thank you very much.
Michael Stubblefield: In the near term, he is working closely with the commercial team to grow and retain key accounts and aggressively pursue new accounts.
Michael Stubblefield: In addition to the work that Corey has initiated, we have recently implemented a range of actions that will strengthen our business.
Michael Stubblefield: First, our Delivery Excellence Initiative is focused on ensuring greater supply chain efficiency and resilience.
Michael Stubblefield: By improving data accuracy, accelerating fulfillment speeds, and optimizing inventory, we are enabling differentiated service levels to our customers that will drive growth across all channels.
Michael Stubblefield: Second, we are accelerating digital enhancements to our platform, including the rollout of our new AI-enabled e-commerce platform, to further streamline the customer experience. Thank you very much.
Michael Stubblefield: Another important step is strategically optimizing our approach to pricing by leveraging the integration of digital technologies.
Michael Stubblefield: This transformation is expected to unlock new opportunities, maximize value, and improve profitability, and growth.
Michael Stubblefield: The program will be implemented in a phased approach with the first goal-life scheduled for later this quarter. [inaudible]
Michael Stubblefield: We also continue to focus on expanding our portfolio with highly attractive new products.
Michael Stubblefield: In the first quarter, we made meaningful progress with the addition and advancement of several high-impact platforms, including...
Michael Stubblefield: Signing a new distribution agreement with ABKIM, a market leader in the antibody space with over 100,000 skews. [inaudible]
Michael Stubblefield: They will make their high-quality antibodies and reagents available to Avantor's customers across the globe, broadening our collaboration agreement with Fujifilm Irvine Scientific.
Michael Stubblefield: A trusted provider of cell culture media and bio production reagents. The agreement includes enhanced distribution rights across the United States, Canada, Puerto Rico, Latin America, and Mexico, and makes an additional 1,500 skewers fully accessible through Avantor's distribution network. So, I would like to thank you all for your time today. Thank you very much for your time.
Michael Stubblefield: Expanding our Collaborative Distribution Agreement with the Life Science Business of Merck KGA Darmstadt, Germany, for Western Europe . Further leveraging their market leading lab filtration products in our portfolio.
This agreement includes over 1900 skews, encompassing well-known brands.
Michael Stubblefield: and accelerating commercialization and adoption of recently launched J.T. Baker viral and activation solution, which plays a critical role in downstream viral clearance within the monoclonal antibody production workflow.
Michael Stubblefield: This solution is now specified into a significant number of platforms, with many more currently in late stage evaluation.
Michael Stubblefield: While we take steps to accelerate growth, we're also maintaining our relentless focus on efficiency and cost discipline across the company.
Michael Stubblefield: We drove another quarter about performance in our multi-year cost transformation initiative, and remain on track to deliver on our 300 million run rate target, exiting 2026.
Michael Stubblefield: I'm pleased to announce that we have expanded the initiative, and now expect to generate approximately 400 million in run rate gross savings by the end of 2027.
Brent will share more details on this shortly.
Brent Jones: Turning to slide 4, let's take a closer look at our performance.
Brent Jones: In the first quarter, our organic revenue declined 2% year-over-year, driven primarily by underperformance in our lab business.
Brent Jones: While we were awarded seven new contracts and secured extensions of a number of existing contracts in the quarter, including a renewal of our supply agreement with Regeneron,
Speaker Change: The work Corey and his team are doing to accelerate the pace of new account acquisition will be critical to returning this platform to growth. Thank you very much.
Speaker Change: Organic revenue within our bioscience and production segment also came in modestly below plan as growth in processing ingredients and acceptance as well as double digit growth in our single use offering.
Speaker Change: Was offset by weaker demand for our controlled environment consumables that are used to maintain the integrity of our customers' clean rooms. [inaudible]
Speaker Change: While this revenue is sticky and highly recurring in nature, this lower demand is mostly at federal to customers placing tighter controls on usage and response to the current macro environment, while still maintaining throughput.
Speaker Change: Although we are encouraged by in-market fundamentals and conceived momentum in our bioprocessing
Speaker Change: We are not satisfied with overall growth, and are taking action to improve performance across our organization. Despite the top line pressure, adjusted EBITDA margin increase 20 basis points year over year to reach 17%.
Speaker Change: This reflects the continued benefits of our multi-year cost transformation initiative. Adjust the DPS came in at 23 cents, consistent with our plan.
Speaker Change: Given continued macro and policy-related headwinds, we are revising our four-year revenue guidance.
Speaker Change: We expect continued spending caution from education and government customers, especially in the US due to concerns about funding.
Speaker Change: Additionally, the entire market continues to digest potential impact of tariffs, and we have been working diligently to mitigate the impact of current tariffs on our results.
Speaker Change: Based on the tariffs in place today, we have approximately 2% COD's exposure with China, which is our most significant tariff risk.
Speaker Change: Our chair for exposure to the rest of the world is modest by comparison.
Speaker Change: Rebel walk you through the details of our updated guidance at the end of the presentation.
Speaker Change: As I reflect on the quarter and look ahead, I'm encouraged that we deliver earnings in line with our plan despite a challenging external environment. That speaks to the strength of our execution and the benefits of our structural cost actions.
Speaker Change: Nevertheless, we are not satisfied with our growth and we are taking aggressive actions to reignite the top line, regardless of the macro backdrop. [inaudible]
With that, I'll now turn it over to Brent.
Brent Jones: Thank you, Michael. Good morning, everyone. I'm starting with the numbers on slide five.
Brent Jones: Taking into account the divestiture of our clinical services business, together with the impact of FX, organic revenue declined 2%.
Brent Jones: Our sales performance was primarily impacted by the headwinds affecting lab solutions that Michael just discussed.
Brent Jones: While bioscience production overall was modestly below expectations, we saw continued growth with our processing gradients, acceptance and double digit growth in single use offerings. Thanks.
Brent Jones: We also had another strong quarter of order intake, reflecting continued improvement in the bioprocessing and market.
Brent Jones: Adjusted gross profit for the quarter was $535 million, representing a 33.8% adjusted gross margin. This is a decline of 20 basis points a year over year, impacted by the clinical services the vestiture, but a 40 basis points improvement sequentially. [inaudible]
Brent Jones: Adjusted EBITDA was $270 million in the quarter representing a 17% margin and consistent with our expectations.
Brent Jones: This represents a 20 basis point improvement year-over-year and 60 basis points excluding the impact of clinical services.
Brent Jones: Our cost transformation initiative was an important contributor to our margin performance. Notably, adjusted FGNA expense was down $21 billion or 7%.
Adjusted operating income was $243 million at a 15.4% margin.
Brent Jones: Interest and tax expenses were in line with our expectations. As a result, adjusted earnings per share were 23 sets for the quarter, a 1 cent year over year improvement. [inaudible]
Brent Jones: Our adjusted EPS performance in the quarter reflects the flow through of our adjusted EBITDA results, as well as continued reductions in net interest expense.
Brent Jones: Moving to cash flow, we generated $82 million in free cash flow in the quarter. Our free cash flow includes approximately $19 million of one-time costs related to the execution of our cost transformation initiative. Thank you very much.
Brent Jones: Q1's free cash flow was also negatively impacted by working capital timing and annual incentive compensation payments.
Brent Jones: Our Adjusted Net Leverage ended the quarter at 3.2 times adjusted EBITDA. Deleveraging remains our top capital allocation priority and we continue to target adjusted net leverage sustainably below three times.
Brent Jones: Let's now take a closer look at each of our segments. Lab Solutions revenue was $1.07 billion for the quarter, a decline of 3% versus prior year on an organic basis.
Brent Jones: As Michael noted, this decline was due in part to the impact of funding uncertainty within the U.S. Higher Education System, which comprises approximately 5% of our total enterprise revenue. [inaudible]
Brent Jones: These impacts largely manifested in reduced levels of capital spend, along with the general slowdown in lab activity affecting consumables demand as well.
Brent Jones: As Michael noted, funding for bench stage biotech companies continues to be soft, leading to additional demand weakness for this important customer segment in our biopharma and market.
Brent Jones: Finally, we also felt the impact of increased competitive intensity that reduced volumes at a handful of customers.
Brent Jones: Turning to profitability, adjusted operating income for lab solutions was $139 million for the quarter with a 13.1% margin.
Brent Jones: Adjusted operating income margin was flat sequentially from Q4 and up 30 basis points year-over-year, despite the headwinds to the top line.
Brent Jones: The larger performance was driven by strong operational cost management and continued savings for our cost transformation initiative. Thank you, David.
Brent Jones: Bio Science Production Revenue was $516 million in Q1, essentially flat year-over-year on an organic basis.
Brent Jones: Bioprocessing, which represents about two-thirds of the segment delivered low single digit growth. While this is below expectations, the underlying business fundamentals are very encouraging.
Brent Jones: As Michael mentioned, we had solid growth in sales of our processing gradient and acceptance in double digit growth in our single use offerings, including master flex. However, these were offset by lower demand for controlled environment consumables.
Brent Jones: We had yet another quarter of strong order intake within bioprocessing, reflecting ongoing momentum and recovery of the sand market.
Brent Jones: Our new sale-branded silicone's platform grew mid-single digits while electronic materials were stable sequentially with an expected year-over-year decline.
Brent Jones: Adjusted operating income for bioscience production was $123 million for the quarter, representing a 23.9% margin. Adjusted operating income margin was down year over year due to modest freight and absorption headwinds.
Brent Jones: As Michael noted in his opening remarks, we are revising our 2025 guidance to reflect the current uncertainties related to funding and policy-related headwinds and competitive intensity.
Brent Jones: For the full year, we now expect organic revenue growth of negative 1% to positive 1%.
Brent Jones: Our clinical services to vestiture represents a 2% headwind, and based on current spot rates, we now expect a 1% tailwind from FX versus the FX headwind in our prior assumptions. This leads to a reported revenue decline of negative 2% to flat. [inaudible]
Brent Jones: Our key FX assumption is continuation of the dollar-euro exchange rate of approximately 1.12. We also assumed a modest headwind in China related to tariff impacts on demand.
Brent Jones: On a segment basis, we now expect lab solutions growth to be minus low single digits to flat.
Brent Jones: We continue to expect bioscience production to be up mid-single digits. However, due to the headwinds in controlled environment consumables, we now expect bioprocessing growth to be mid-single digits.
Brent Jones: We expect adjusted EBITDA margin to be 50 basis points lower.
Brent Jones: 17.5% to 18.5% while adjusted EPS and free cash flow remain unchanged.
Brent Jones: at $1.02 to $1.10 and $650 million to $700 million, respectively.
Brent Jones: In terms of Q2, we expect organic revenue growth to be flat to modestly up.
Brent Jones: Our clinical services divestiture represents a 3% headwind, and based on current spot rates, we expect a 1.5% tailwind from FX.
Brent Jones: This leads to reported revenue growth of flat to modestly down year over year. On a segment basis, we expect lab solutions to be flat to modestly down and bioscience production to be up mid-single digits.
Brent Jones: We expect modest sequential improvement in EBITDA margin to the mid-17s.
Brent Jones: We expect that the external environment will continue to be dynamic, particularly with respect to the potential impacts of a global restructuring of international trade agreements and related taxation.
Brent Jones: While our manufacturing footprint and supply chain are significantly in-ringing for-region, we do have a meaningful amount of cross-border trade, particularly in our lab solutions business.
Brent Jones: The updated guidance does not assume any material impact to demand or earnings from the potential terrorists.
Brent Jones: In the event renegotiate trade agreements do not adequately prevent tear-related headwinds, we are prepared to mitigate by leveraging our global supply chain.
Brent Jones: We have a broad product offering that gives our customers optionality, and we will work closely with our customers to ensure that we are able to offset tariff surcharges to the extent possible.
Finally, an update on our cost transformation.
Brent Jones: This initiative has not only made a material impact on our financial results, but it has also sharpened our focus on conversion to the bottom line and to cash. Our actions have been carefully designed and executed to ensure that our critical capabilities remain intact.
Brent Jones: As a reminder, we exited 2024 with over $130 million of in-year savings and an exit run rate of approximately $165 million well ahead of plan.
Brent Jones: In 2025, we expected to generate an incremental $75 million of end-year gross savings and exit 2025 with run rate savings in excess of $250 million. $70 million.
Brent Jones: We have clear line of sight to exiting 2026 with the promised $300 million of run rate cost savings.
Brent Jones: As we more deeply live into our new segments and operating model, we continue to identify further opportunities for productivity. As a result, we are expanding the initiative and now expect to exit 2027 with at least 400 million of run rate cost savings.
Brent Jones: While we aren't currently forecasting material impact to fiscal 25, we are committed to front-loading the incremental savings as much as possible.
Brent Jones: In the current environment, we believe it is critical to control our controllables as much as possible, and these incremental cost actions are an important example of this. With that, I will turn the call back to Michael. Thank you for your time.
Thank you, Brenn.
Michael Stubblefield: Before we move into Q&A, I would like to briefly recap today's key takeaways and reiterate our priorities moving forward.
Michael Stubblefield: First, we remain confident in the strength and resilience of the Avantor platform.
Michael Stubblefield: Our lab solution segment is built on differentiated capabilities, a broad and expanding portfolio, and global supply chain that enables us to reliably serve our customers around the world.
Michael Stubblefield: Second, our multi-year cost transformation initiative continues to be a powerful driver of margin expansion and strong free cash flow.
Even as we navigate near-term, top-line headwinds. [inaudible]
Michael Stubblefield: We are expanding this initiative and remain committed to best-in-class operational discipline and execution.
Michael Stubblefield: Finally, while growth, particularly in lab solutions, is not what we want it to be. We are taking decisive action.
Michael Stubblefield: Under Cory Walker's leadership, we are strengthening the foundation of the business and enhancing the commercial strategy to position lab solutions for long term success. Thank you very much.
Michael Stubblefield: We look forward to updating you on our progress in the quarters ahead.
Michael Stubblefield: With that, I'll now turn the call over to the operator to begin the Q&A session.
Speaker Change: Thank you. To ask a question, please press Start followed by 1 on your telephone keypad now. If you change your mind, please press Start followed by 2.
Michael Stubblefield: When preparing to ask your question, please ensure your device is unmuted locally. Please limit yourself to one question and one follow-up question.
Speaker Change: We have a question from Michael Ryskin with Bank of America. Please go ahead.
Michael Riskin: Great. Thanks for taking a question. I guess my first one, Brennan, I'll just ask on the guidance because that's kind of where you left off. The 2Q guide, I think you said, you know, mid-single digits, BTS.
Speaker Change: You know, flat the modestly up for the whole company. That seems like a pretty aggressive...
Step up from one cue, both in terms of...
percentage growth. [inaudible]
And just a dollar amount. [inaudible]
Speaker Change: You know, was there anything timing related in any of that, you know, clean room controlled environment? Was there anything timing related with some of those customer agreements? You know, are you expecting any change in the underlying market? Just sort of what's driving that improvement? You know, both one key to two key and for the rest of the year to hit your your revised guide? Okay.
Yeah, Michael, thanks for the question there. We're-
Speaker Change: It's really a continuation of the current environment there. I mean, when you're talking about growth right here, there are always a year over a year, so what's going on? It's comparable. It's comparable.
Speaker Change: Q2 is always a very strong quarter for us, and obviously it's informed by all the momentum we're seeing in the quarter so far here. So I think the other piece I'd add is we thought very carefully about it.
Speaker Change: The re-guide for the year as well as Q2, and you know, use the line I use all the time, we think we have a balance of...
Speaker Change: We think it's an important way to prove it there. We really view the BPS Q1 as an anomaly there and in terms of timing of things. Thank you very much.
Speaker Change: We think that's a very sensible guide for the full year, so we're comfortable with what we put out there.
Speaker Change: Okay, and then for the follow-up, I think you called out 2% crocs, it's those that shine as you're more significant one.
Speaker Change: Just to be more specific on tariffs, do you say what are you factoring into the new fiscal year guide? You know, I saw that you didn't change your EPS number. So, are you, are you offsetting some of that exposure with price or with other mitigation techniques? [inaudible]
Speaker Change: Just sort of like what's built into your God from a tariff fit now? No.
Yeah, so.
Speaker Change: So what we've said specifically there is, for the full-year guide, we have some modest demand reduction in China, as you'll recall, we don't—
Speaker Change: Have significant revenue in China there, so that's a very modest piece, and that's...
Speaker Change: We don't have any significant tariff assumptions built into the guy here that we'll walk through the specifics. The primary exposure there is the 2% of cogs related to China, as we know in the remarks.
Speaker Change: We have a number of believers in Region 4 region, alternate suppliers, we have a wide...
Speaker Change: Ray of Materials. Again, this is primary lab solutions dynamic, and obviously it's off set with price. And if these things became very material, that could adjust things. But we're taking a no impact to the guide from tariffs. [inaudible]
Okay, thank you.
Thank you.
Speaker Change: Thank you. Our next question comes from the line of Vijay Kumar with Evercore. Please go ahead, Vijay.
Pre-trial Environment Substance.
Vijay Kumar: But my understanding is these are products which should be tied with the production volumes.
Speaker Change: So, is that true in the episode? And, you know, why were customers cautious in that Q1? Was it just a climbing of order?
Speaker Change: In a timing element, and that's what gives you the confidence here why BPP should go be up mid-singles in the true cure. Thank you.
Vijay Kumar: Good morning, Vijay, and thanks for the questions. I think that is a really great place to start. When we unpack the performance in DPS,
Speaker Change: Sagnant, you know, consistent with what we said, you know, generally across the enterprise, we're not thinking entirely satisfied with where the quarter played out. [inaudible]
Speaker Change: And, you know, I've taken, you know, a number of actions to address the pockets of weakness that we saw in the, in the quarter and we're certainly starting to see, you know, even over the last several weeks, you know, some impact of some of those actions. [inaudible]
Speaker Change: Now in a little bit more granular level, when we look at, you know, bioprocessing, which is about two-thirds of the-
Speaker Change: The revenue on that platform, we remained incredibly optimistic about the end market fundamentals there. We had a great quarter on, you know, plus ingredients, ingredients, ingredients, we highlighted, you know, double-digit growth on single use, including master flags.
Vijay Kumar: You know, that was, you know, offset in the quarter of why headwinds in the controlled environment, consumables category that you mentioned, Vijay.
That's an important part of the platform.
Vijay Kumar: In that, it helps maintain the integrity of these clean rooms. It's specified into these clean rooms. It's quite sticky and revenue.
Vijay Kumar: What we were seeing in the quarter was customers looking for various levers to address the macro headwind including inflation and serving opportunities that they had in the quarter. Number two.
optimized usage.
Vijay Kumar: We're leaning in there and, you know, we're optimistic about or encouraged by, you know, some of the actions that we've taken there and, you know, just given the strength of the, the order book across the, the biopathesting platform there.
Vijay Kumar: Continue to be encouraged by the trending that we're seeing there, and you'll feel really confident about the outlook that was given here today. Thank you very much.
Speaker Change: Mr. and maybe my follow-up is done on the lab side. I think you mentioned higher comparative.
intensity, maybe if you could just elaborate on that.
The Comparative Dynamics, with the channels part of the business.
Speaker Change: That's a great question, Vijay. We've talked a lot to early marks today about the macro environment and the man headwinds that we're seeing across the market, given a lot of the funding and policy related. [inaudible] We've talked about the macro environment
Speaker Change: Headwinds that all of us in this space are experiencing. And it's against that macro backdrop that we do see a heightened level of competition. And at an account level, that heightened competition does manifest itself in different ways. [inaudible]
Brent Jones: You know, we highlighted, you know, quite a number of new account wins and extensions, including a really important extension with with Regeneron. But as Brent noted in his remarks, we also did see, you know, some shifting, you know, within a few of. [inaudible]
Our accounts that did lead to lower volumes. Now.
Brent Jones: You know, against that macro and competitive backdrop, I think it highlights the importance of the decisive actions that we are taking today to strengthen the business.
We're certainly focused under Cois leadership here of...
Brent Jones: Driving aggressively to retain and grow our key accounts. And the overall action plan that we put in place here is really meant to strengthen the business regardless of the macro backdrop that we're in. [inaudible]
[inaudible]
Speaker Change: Thank you. The next question comes from Rachel Rantin's door with JP Morgan. Please go ahead, Rachel.
Speaker Change: Great good morning and thanks so much for taking the questions today. So I wanted to dig into the performance within lab solutions. You highlighted some of the weakness with an academic and government, given that five percent of your total revenues.
Speaker Change: You also noted that there's not only weakness on the capital equipment side but also on the lab activity side, so can you break down for us? What did you see for equipment declines within your academic and government customers? And then also what did you see for consumable declines? And then what did you see for consumable declines within your academic and government customers?
Speaker Change: And then, within that segment, overall, for Academic and Government, what are you assuming for the clients this year? [inaudible]
And I'll have to hit a guide. Thanks. Thanks.
Speaker Change: Yeah, thanks for the question, Rachel, obviously very relevant for the environment that we're in.
Speaker Change: So just to recap a couple of key points here around the performance in the quarter lab platform for us, roughly 3% in the quarter. And as we think about how we're reflecting the current macro environment in the updated guidance that we've provided.
Speaker Change: We're really using a lot of the same approach that we had last year, where we're projecting, you know, current, you know, trends persist through the balance of the year. We have baked in the headlands that we're seeing here, particularly in the academic and government environment as you suggest. Thank you guys.
Speaker Change: In the U.S. higher education market, the sentiment did turn decisively even more cautious, following announcements of the NIH, funding actions, and we saw that manifest itself with customers in a number of ways, firstly. [inaudible]
All right.
Speaker Change: Looking to optimize existing cash and funding, and so you do definitely see a pullback in equipment and instruments.
Speaker Change: Also, you know, just some caution on, you know, hiring of new, you know, scientists initiating of new programs.
Speaker Change: Which is a part of how we grow that business and that's where the consumable speech of this comes in is. [inaudible]
Just, you know, a muted level of activity generally speaking. [inaudible]
Speaker Change: Given the uncertainty these universities have around funding on a full year basis. But when we look ahead here together with the actions that we're tanking to strengthen the business, we think that the current environment is well covered in our updated outlook for the year. [inaudible]
Speaker Change: Read, and then just from a follow-up here, I just wanted to dig into some of the pricing dynamics.
Speaker Change: So, you've highlighted some of the weekends funding on not only the biotech side but also with your academic and government customers, also just the broader environment with Tyros as well. So, there's a few moving pieces on the pricing front.
Speaker Change: I believe your prior assumption that the guidance was 1-2% price in contribution for the year.
Speaker Change: So what is your ability to take price in this new regime that we're seeing relative to a few months ago, and what are you assuming for pricing contribution in the guide?
Speaker Change: And then, if I continue to follow up, I'm getting a bunch of questions on the tariff answer earlier in the discussion. Can you just clarify for us, is that 2% China cause is that going to be fully absorbed in the guidance or is that not baked in at this point? [inaudible]
Speaker Change: Happy to address both of those. I'll cover the pricing questions, Rachel, and we'll have Brent give you some additional detail on from the tariffs there. So as you know, pricing is an important part of our our algorithm here and.
Speaker Change: The level of impact, I think you highlighted, I think is appropriate way to model this. And as we got into the year and you got through contracting season and price administration, I think it's played out largely as we had expected in and lying with.
Speaker Change: The guidance that we had given there, probably the one dynamic to consider, which is reflected in Q1 as well as through the rest of the year, is just the increased competition for new accounts, new business.
Speaker Change: You know, that is printing at, you know, modestly lower margins than what we, you know, would typically see, you know, just given the competitive intensity there. But, you know, for the business that we have today and for the contracted customers, pricing has played out. [inaudible]
Speaker Change: Nothing I would point out or highlight or pick you back to is the actions that we outlined that we're taking to strengthen the business.
Speaker Change: One of those is in the pricing area, and while we think we're pretty good at this, and it is a complex platform that we run to administer pricing across six million skews.
Speaker Change: You know, we are, you know, taking some additional steps and then making some additional investments, strengthening our pricing capabilities.
Speaker Change: We're really looking to leverage the integration of a number of digital technologies that will significantly advance our capabilities in this area, making us more agile, able to do more tailoring, and in this dynamic environment, the capabilities that we're adding here, will enhance profitability. And growth, and that will go out on a face approach.
starting here this quarter.
Speaker Change: Brantula, answer for paraphrasing. Sure, Rachel. So the 2% of colleagues was dimensionalizing the total exposure. We did have the other comment on, we have taken a little demand out in China there.
Speaker Change: on the revenue side, but on the cost side, the 2% of the cards, is the exposure. We have not explicitly included that in the guide for all the commentary. We will do everything to offset that.
Speaker Change: You know, one day the paraphrase are actually other than why, you know, our view is don't overrespectfully, we just indicate there's a risk around that and we're doing everything we can to execute around it.
Thank you.
Speaker Change: Thank you. Our next question comes from the line of Tycho Peterson with Jeff Reed. Please go ahead Tycho.
Tycho Peterson: Hey, thanks. Michael, I'll take the bait on the bioprocess order book. You characterize it as strong. Just maybe a little more color on demand trends. You know, I assume book a bill above one. Can you maybe just give us some flavor of what that looks like? And, you know, is this mostly emerging biotech? Is it CDMOS? A little bit of a market mix color too? Thanks. Yeah.
Tycho Peterson: That's a really important point to articulate here today is we are optimistic about the end-market fundamentals and that's really informed by now well more than a year of momentum that we see not only on the top line but also in the building of the order book which gives us confidence in the...
Tycho Peterson: The Outlook. And we see that strength in order book, which you can assume is as strong as some of the other numbers that you've seen printed if not stronger.
Tycho Peterson: And so, you know, it's pretty safe to assume, you know, with the blood exposure that we that we have in the momentum that we see that we don't really see a lot of differences, you know, between, you know, large pharma, biotechs, you know, CDMOs, we see the strength, you know, pretty uniform across the space. [inaudible]
Speaker Change: Okay. And then back to the issue on the controlled environmental consumables, can you just break out the percentage of revenues or mix, you know, I mean, we've never really heard you talk about this before. So how large is it? And what do you think it takes to turn it around? I mean, we're still in a tough, you know, a budget environment. So is there anything you can do proactively? Absolutely.
Speaker Change: Great questions, Tycho. So, we actually incorporate that into our, you know, bioprocessing, you know, categorization, which is what's included in the 2-thirds of our revenue.
Speaker Change: And, you know, classically, that application, you would reliably grow, you know, mid to high single digits, and, you know, even as recently as fourth quarter. [inaudible]
Executive, Christina Jones, Michael Stubblefield
Speaker Change: You know, kicked into action and we have, you know, really ramped up commercial intensity and account level activities. [inaudible]
Speaker Change: To drive and improve performance there. And when we look at order trends, data rate of sales over those categories over the last month or so, I think we're encouraged by the actions that we're taking or certainly having the intended effect and moving things in the right direction here. [inaudible]
Thank you.
Thank you. Thank you.
Speaker Change: Thank you. Our next question comes from Daniel Brennan with TD Cohen.
Dan, please go ahead.
Speaker Change: Great, thank you. Maybe just one back to the tariff situation, sorry, to kind of revisit this. That's what kind of makes me understand it. So for the 145% tariff that the US is placing on China, so that's 2% of COGS.
Speaker Change: Brandon, it sounds like you guys are not including any impact from that. I know you're talking about you all said it. I'm just trying to figure that out and could you speak a little bit to more broadly, what percent of your US sales are sourced? [inaudible]
Speaker Change: OUS, so if you, you know, even outside of China and Europe , because they're still expected to be, you know, right now a 10% minimum tariff on those. I'm just trying to figure out like, have you, have you assumed those impacts and you're just trying to offset them, or you're not assuming those impacts of all would be my first question. [inaudible]
Speaker Change: Yeah, Dan, so we're not assuming those impacts. It is so dynamic right now. As we noted, the China exposure is the lion's share of the exposure. We do have some of the other jurisdictions that's obviously...
Speaker Change: significant difference, you know, 135, 145% were 10% tariffs there, but the exposure to shine and dwarf the other ones.
Speaker Change: We will do our best to offset. But again, the environment is so dynamic. We, if we renew any estimation, we'd have there would be wrong. So,
Speaker Change: That's the approach we're taking. And then maybe just to follow on and add a little bit more color to the topic and put that 2% of cogs in context. You know on our. [inaudible]
Speaker Change: Our cost basis that we have, that would be in the current. [inaudible]
Speaker Change: What we know currently about the tariffs on imports from timing to the U.S. That's less than $100 million of exposure for us.
Speaker Change: And, you know, I think it's important to highlight the number of levers that we have to offset that, whether it be, you know, alternate sourcing optionality for our customers. Thank you very much.
Speaker Change: We have a significant number of the skews that we've purchased out of China that can be sourced from other suppliers that are specified into our customer's work clothes here and it would be appropriate for them to use.
Speaker Change: We have inventory hedges against some of these things, and ultimately... [inaudible]
Speaker Change: We have the flexibility to incorporate tariff surcharges as necessary, but the situation is extremely fluid. There's been talk this week that perhaps the rate could cut in half, so we're continuing to follow it closely. We're working closely with our customers on how best to mitigate this and I think we're in the position to offset this as it pays out.
Thank you.
Speaker Change: Got it. And then maybe just to follow up on the lab side. I know there's been a few questions asked, but just. [inaudible]
Speaker Change: We'd love to unpack that a little bit more, so could you to speak to what happened to your higher ed business in the quarter? Kind of what you're assuming? And then I don't know if you sized it. The Ben stayed biotic business, which you talked about being weak. [inaudible]
Speaker Change: How big is that? And kind of how have you thought about that outlook? And then I apologize, you know, you talked about the competitive intensity.
Speaker Change: Michael, you and I have spoken that there's a lot of mom and pops.
Speaker Change: Distributed still out there, so it's not just you in Dermot. So I'm just wondering if you could speak a little bit. Also, does unpack that a little bit like it sounds like you awesome share in the quarter. Just wanted to understand like if you think about the overall market for lab distribution, are you growing well below that now or are you still growing roughly online. Thank you.
Speaker Change: Yeah, I mean, do my best to unpack, you know, the questions that I think, you know, the heart of it, obviously, rests on, you know, our shared, you know, disappointment with the performance of the platform in the quarter and underscores, you know, the importance of having Cory on board here and, you know, the aggressive actions that were that we're taking. We acknowledge the macro backdrop is challenging. It's challenging for everyone right now. And, you know, we're not just trying to hide behind that and certainly during [inaudible]
Speaker Change: and Bob Cook biblical. So again, these are two great books on reading each other, really. I highly recommend it. And, that is it for though. Thank you for watching. Thank you for listening to us put out this recitation. In the meantime, if you've reached this point already, please feel free to give us your feedback in the comment column. We really appreciate it, and we look forward to seeing all of you back in the year. Thank you very much. SKC. Thepertfected.com Cont Shop Presents, the Paramount News Gear Continue to focus on the Parament Study and Paragraph Diversity. We've talked before about uniforms. What are you looking forward to?
The
Speaker Change: Edwin's in, you know, funding or socially funding uncertainty and academia and government I think are well documented. You know, as a category, you know, at an enterprise level, I think you'll see in, you know, some of our disclosures today, you know, we're off mid-single digits for the portion of that that's in the US, you know, you're off well into the double digits and, you know, we have. [inaudible]
Speaker Change: That is, I think, a number of occasions at an enterprise level that's low single-digit exposure for us, but it's all in the lab. And when you flip it into the lab segment, that's probably around 10% of our overall exposure. And, you know, similar to the assumptions we've made on academia and government reflected in the current guidance is that those...
Speaker Change: You know, headwinds persist through the balance of the year. We're not incorporating, you know, any recovery, you know, for that. And, you know, of course, we are taking actions and, you know, as those actions take hold on successful, you know, that could provide us from outside to, you know, where we're asked. [inaudible]
Speaker Change: The market isn't a duopoly, it's highly fragmented. There are a number of players here while facing the same challenges and I think we're navigating the headlands and the competitive intensity as well as anyone.
Speaker Change: You know, in the quarter, certainly we did see, you know, some movement at, you know, some of the accounts. Well, it's not a number of wins. And so it's, you know, it's hard to say, you know, how. [inaudible]
Speaker Change: You know, how a number is compared to others, other than to acknowledge, we're not satisfied with it. We're well positioned, you know, to serve this space. And, you know, as the actions take hold that we've, we've initiated in the market recovers the well position for long-term broker.
Dr. Ryskin.
Speaker Change: Thank you. Our next question comes from Doug Schenkel with Wolf Research. Doug, please go ahead.
Speaker Change: Good morning, and thank you for taking my questions. And before asking my two, I just want to thank you, Michael, for all your help over the years. So I know today's not the end, but I know you're moving out, so congrats on that again. Thank you for all your help. So, thank you, you know, on just a couple of things, first on bio processing. [inaudible]
Speaker Change: Obviously this has come up a little bit, but on one hand, you sound...
Good on the order, book and friends.
Speaker Change: On the other hand, you lowered expectations for bioprocessing. Is that largely just a function of the environment and wanting to be a little bit more conservative given everything that's going on outside your control in spite of the fact that that business actually looks okay? All right.
and then the second topic is really a longer-term question.
I...
Speaker Change: I think a lot of us appreciate the efforts you're making to aggressively control what you can control in terms of cost, in a scenario where the company returns to more normalish mid-single digit level growth in 2026 with higher growth from higher margin businesses.
Speaker Change: It seems like mathematically you could drive 100 to 150 basis points of margin expansion in that scenario. Again, I'm not asking you to guide, but I just want you to tell me if I'm doing my math right. Thank you. Thank you.
Speaker Change: Both very good questions, Doug. Let me take the first form of bioprocessing and we'll have Brent to give you some color on incremental margins as growth returns to the platform. [inaudible]
So, starting with...
Speaker Change: BPP, our bioprocessing platform. There is a lot of momentum. I just reiterate what I've already said. We're encouraged by the in-market fundamentals. And our order book has been strong. And that's across that platform, whether it be processing readings or single use, or even controlled environment consumables.
Speaker Change: The guide at mid-single digits that Brent outlines does reflect the low-single digit growth of the platform in Q1 and rolls that into the full guide here.
Speaker Change: But when we look at the order block and the trending that we're seeing, we do see the incremental improvement in the business, particularly here in the second quarter.
Speaker Change: And, you know, things that the guide is, you know, to use Princeward is prudent. We thought about it, you know, quite carefully, and you're looking at the positioning and the data. We are taking action similar to what we're doing on lab to, you know, to drive the business. [inaudible]
Speaker Change: You know, I think there's a lot working here in our biopositing platform to be excited about.
Speaker Change: Doug, talking about the margin point, and again, absolutely not making the future guidance there, but look, <expletive> , just with...
Speaker Change: Particularly what we can do on the BPS side of the business, incremental margins. You can print their fantastic, what you get to the right levels of growth. [inaudible]
Obviously the lab.
Speaker Change: You know, the Latin growth, the growth, we do have meaningful fixed cost against that and that impacts margins for sure. You know, we've talked about the 20% EBITDA on margins last year. [inaudible]
Speaker Change: In 1996, accounting for the clinical services to vestiture. This platform absolutely wants to be above 20% margin there. We just need the right growth entitlement against it. And I think your comments absolutely correct there, but let's get further in the year, let's get back. Thank you very much.
Speaker Change: To the right kind of demand environment, and that'll absolutely be a topic when we begin to
Speaker Change: Thank you. The next question comes from Luke Sergott with Barclays. Luke's please go ahead.
Luke Surgott: Great, thanks guys. I just want to talk about the business transformation.
Speaker Change: And especially on the lab science side, you're just talking about doing the improvements there, like...
Speaker Change: How much of the change that you're taking a look at is due to a substandard or suboptimal portfolio? I'm just trying to get a sense of what you guys need to do from an investment standpoint to kind of send off the...
The Competitive Dynamics there.
Good questions, Luke.
Speaker Change: where I'd start with that is just highlighting, you know, our
Speaker Change: you know, focus on enhancing and positioning the growth of that business, you know, to weather the current macro environment. And there's going to be a lot of aspects to it. You know, Corey's now been on the ground here for a month, fortunately, you know, he knows the business well from his time here before and has ramped, you know, quickly and he's moving, you know, aggressively.
Speaker Change: to interrogate the business strategy and execution of maybe nurse stone on the turn and working very, very closely with the commercial team.
In the near term, to drive.
Executive, Christina Jones, Michael Stubblefield
Speaker Change: As always, continuing to drive innovation into our portfolio, and we're really excited by the content that we were able to add to the portfolio in the first quarter. And I wouldn't say in these actions are specific to one single data point we're getting out of the...
Speaker Change: The business and this environment and strength in it, and I think we're confident in the actions that we're taking will give us the best chance to grow this platform on-term.
Speaker Change: All right, great. And then, just to follow up here, talk about that. [inaudible]
Brent Jones: You know, the incremental $100 million on the cost out. Brent, you talked about trying to do what you can and front load that in the earlier years. Like, what can you do?
Brent Jones: Just taking a little bit more there on specifics that you run the risk there or have to strike a balance without this rupting your overall sales force or the momentum you're trying to build within the two segments.
Speaker Change: Yeah, Luke, that's absolutely very well taken, and we tried to address a little bit of that directly in the prepared remarks. I mean, I think the first thing I'd start with there is
Speaker Change: The program today, we think it's been done really clean, hasn't led any disruption. I mean, look at the end of the day, even though we want to rationalize the cost-based, job one has grown. Absolutely focused on growth across both sides of the business. And...
Speaker Change: I think another reason we've executed so rapidly, or at consequence of that, as you want to minimize the disruption to the org. So moving to the laps to the speakers is really valuable there. Some of these things, I mean, these really are the insights towards leadership is going to be really helpful for it as well. Thank you very much.
Speaker Change: But just as you understand, the segment structure is better here, that unlocks sort of more of what we have existing, but some of these things will take some time, but they're really important, like...
Speaker Change: We're going to have an initiative on digitization and connection with manufacturing. That's going to both make...
Speaker Change: Go long ways towards delighting our customers, as well as really enhancing our cost. Michael made a number of the comments on.
Speaker Change: You know, tech enablement on pricing. You're going to see that for many other commercial pieces. It's so.
Speaker Change: Thank you. Our next question comes from Tengar Savant, but Morgan Stanley , please go ahead.
Hey guys, good morning and thanks for the time. Thank you.
Speaker Change: Brent, maybe starting with you at a relatively high level, you know, that 200-bit reduction in organic growth, can you just bridge us?
Speaker Change: To that, between education and government, the controlled environment, consumables, the competitive intensity you guys cited, and then a little bit of a haircut on China. Like if you were to parse it out, that 200 bits, how would you do it? [inaudible]
Speaker Change: Yeah, I, what I do bridging that to us is it's it's almost
Speaker Change: It's largely driven by the policy environment and then the biotech funding piece. So it's largely about solutions when you look at the underlying statement piece of it. [inaudible]
Speaker Change: Very modest piece on the critical environment, and our Chinese sales are so small there that wouldn't be a significant portion of the bridge. So it's all—
Speaker Change: In many respects, when you think about it, it's taking the Q1 rates on growth and really extending them to the year and you can see sort of the Q1 decrement really is what we're turning into the full year guide update.
Speaker Change: Got it, that's helpful. And then Michael, one for you again, at a high level, you know, last quarter we spoke a little bit offline about, you know, your ability to help customers navigate the shifting path environment and some of the supply chain be risking that they're looking to do. [inaudible]
Speaker Change: Why isn't this an opportunity for you to perhaps even, you know, gain some share from customers who are, you know, currently sourcing direct or sourcing from smaller distributors in the months ahead of vendor consolidation as a team we are about from some of these customers?
Speaker Change: Convertly, are any of your customers choosing to go direct and just sort of disintermediate the middleman or in combination with this increased competitive intensity you called out, does that just nullify any benefit from potential share gains at the moment?
Speaker Change: Great questions, you know, Pages, when we look at the environment that we're in and particularly. Thank you very much.
Speaker Change: The global nature of our supply chain, the broad product development and optionality that it gives our customers. We think we are uniquely positioned to support our customers through this challenging environment.
Speaker Change: And in times of dislocation like this or where there's friction in the system, it certainly gives you an opportunity to get close to your customers and be a solution provider to them. And given all the flexibility that we talked about and optionality that we offer.
Speaker Change: We are working very closely with our customers. Both existing as well as potential that are looking to find ways to address the current macro.
headwinds at the wall facing. [inaudible]
Speaker Change: And so, yeah, certainly would never want to imply for remarks today that we're not looking at it that way. And with the work that Cory is certainly leading together our commercial associate who are. [inaudible]
Executive, Christina Jones, Michael Stubblefield
In an environment like this, and your point there about...
Speaker Change: You know, are folks cutting out the middleman? That's not a trend that we've experienced in this environment. And that's largely just due to the value proposition and strength of the supply chain that looks like ours, the unparalleled customer access that we provide the agility, the choice, and the ability to serve these customers the way we do really is an important part of our differentiated platform here.
Speaker Change: Got it. Appreciate the color, Michael. Thank you, and thanks for the help of the earth.
Thank you.
Speaker Change: Thank you. Those are all the questions we have time for today, and so I will hand back to Michael Stubblefield for closing remarks.
Speaker Change: Thank you all for joining us today as you've heard through our prepared March and through our Q&A session here. We are not satisfied with our overall results and hopefully you sense the urgency that we're moving to enhance performance and maximize value in this environment, including through the upsizing of our cost reduction initiatives.
Speaker Change: The board and our entire leadership team are committed to achieving this objective. And we look forward to discussing our progress as we move forward. Until then, be well everyone. Thank you.
Thank you everyone for joining us today.